Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsANIP -5.35%80 OCF Margin % is 24.58% as of Mar. 2026, which is 16% above its 10-year median of 21.17. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 963 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 83.49% on this metric.
The historical data trend for ANI Pharmaceuticals's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (ANIP) has a OCF Margin % of 24.58% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ANI Pharmaceuticals and its competitors. This is 16% above median its historical median of 21.17. According to the industry distribution chart, ANI Pharmaceuticals ranks #159 out of 963 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is ANI Pharmaceuticals' OCF Margin % too high?
ANI Pharmaceuticals' current OCF Margin % of 24.58% is 16% above median its 10-year median of 21.17. The Drug Manufacturers industry median OCF Margin % is 9.94. ANI Pharmaceuticals' value of 24.58% is 147.3% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #159 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' OCF Margin % compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #159 out of 963 companies for OCF Margin %. This places ANI Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. ANI Pharmaceuticals' value of 24.58% is 147.3% above this benchmark. While the company's 10-year median is 21.17 vs. the industry median of 9.94, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current OCF Margin % of 24.58% is 147.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current OCF Margin % is 24.58%, which is 16% above median its own 10-year median of 21.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.57, compared to a current price of $78.45 — trading 22.8% below its estimated fair value. The current OCF Margin % is 24.58%, which is 16% above median its 10-year median of 21.17 and 147.3% above the Drug Manufacturers industry median of 9.94. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current OCF Margin % is 24.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $78.45 is trading 22.8% below its estimated GF Value™ of $101.57.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
OCF Margin %: 24.58% (16% above median its 10-year median of 21.17)
GF Value™: $101.57 vs. price of $78.45 (22.8% below fair value)
Industry Position: 147.3% above the Drug Manufacturers median (#159 of 963)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score
Get the complete analysis for ANIP
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
